![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Defizite in der Behandlung von Patienten mit kolorektalem Karzinom in Deutschland
Seit etwa 10 Jahren existieren Konsensusempfehlungen zur adjuvanten Therapie des lokal fortgeschrittenen kolorektalen Karzinoms (amerikanisches National Institute of Health 1990, Deutsche Krebsgesellschaft 199...
-
Article
Should bevacizumab be continued beyond progression in colorectal cancer?
Medical therapy for advanced colorectal cancer has seen significant changes over the past decade. Most recently, molecular targeted agents such as antibodies against the epidermal growth factor receptor and th...
-
Article
Adding cetuximab to a standard chemotherapy regimen containing bevacizumab in first-line therapy for colorectal cancer decreases efficacy: Results from the CAIRO2 trial
-
Article
Strategies for Managing Chemotherapy-Induced Sensory Neuropathy
Chemotherapy-induced sensory neuropathy occurs in most patients undergoing treatment with oxaliplatin for colorectal cancer. Although the acute form of neurotoxicity is transient, the chronic form, which is co...
-
Article
Reduced Chemotherapy Duration: A Good Idea?
Over the past three decades, survival outcomes of high-risk stage II and stage III colon cancer have improved with the use of adjuvant chemotherapy. Oxaliplatin and fluoropyrimidine combination regimens, given...
-
Article
Optimal Treatment Strategies for Localized and Advanced Microsatellite Instability–High Colorectal Cancer
The defective mismatch repair phenotype (MMR-D) has been recognized as a distinct form of colorectal cancers with specific clinical and biologic features. It is caused by a lack of expression of mismatch repai...
-
Article
Open AccessThe IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current Status
The International Duration Evaluation of Adjuvant Chemotherapy (IDEA) collaboration was established to prospectively combine and analyze data from several randomized trials conducted around the world to answer...
-
Article
Distinctive Tumor Biology of MSI-High Colorectal Cancer
High-frequency microsatellite instability (MSI-H) accounts for roughly 15 % of all cases of colorectal cancer (CRC) and results from pathogenic mutations or epigenetic changes in mismatch repair (MMR) proteins...
-
Article
New Adjuvant Trial Designs in Colon Cancer
The treatment of colon cancer has evolved significantly since the discovery of 5-fluorouracil, and with continued innovation, it will continue to advance for the foreseeable future. In this review, we identify...
-
Article
Precision Medicine for the Treatment of Colorectal Cancer: the Evolution and Status of Molecular Profiling and Biomarkers
The application of advanced genomic testing to develop tumor-specific molecular profiles is essential to facilitating precision medicine pharmacotherapy. These approaches are highly relevant in colorectal canc...